{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:00:25Z","timestamp":1775696425689,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00280-017-3341-6","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T15:29:53Z","timestamp":1495553393000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Yoshiki","family":"Hirooka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eizaburo","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nonogaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"issue":"1","key":"3341_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/annonc\/mdn533","volume":"20","author":"G Randi","year":"2009","unstructured":"Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20(1):146\u2013159. doi:\n                        10.1093\/annonc\/mdn533","journal-title":"Ann Oncol"},{"issue":"30","key":"3341_CR2","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1200\/JCO.2005.02.7524","volume":"23","author":"J Gallardo","year":"2005","unstructured":"Gallardo J, Rubio B, Villanueva L, Barajas O (2005) Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 23(30):7753\u20137754. doi:\n                        10.1200\/JCO.2005.02.7524\n                        \n                     (author reply 7754\u20137755)","journal-title":"J Clin Oncol"},{"issue":"14","key":"3341_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABCT Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. doi:\n                        10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"8","key":"3341_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","volume":"90","author":"DC Doval","year":"2004","unstructured":"Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90(8):1516\u20131520. doi:\n                        10.1038\/sj.bjc.6601736","journal-title":"Br J Cancer"},{"issue":"2","key":"3341_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/14656566.6.2.211","volume":"6","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, O\u2019Reilly EM (2005) Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother 6(2):211\u2013223. doi:\n                        10.1517\/14656566.6.2.211","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"3341_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2(11):1245\u20131248. doi:\n                        10.1200\/JCO.1984.2.11.1245","journal-title":"J Clin Oncol"},{"issue":"8","key":"3341_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.1996.14.8.2306","volume":"14","author":"DV Jones Jr","year":"1996","unstructured":"Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14(8):2306\u20132310. doi:\n                        10.1200\/JCO.1996.14.8.2306","journal-title":"J Clin Oncol"},{"issue":"10","key":"3341_CR8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","volume":"12","author":"JO Gallardo","year":"2001","unstructured":"Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12(10):1403\u20131406","journal-title":"Ann Oncol"},{"issue":"4","key":"3341_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study\u2014The UK ABC-01 Study. Br J Cancer 101(4):621\u2013627. doi:\n                        10.1038\/sj.bjc.6605211","journal-title":"Br J Cancer"},{"issue":"4","key":"3341_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469\u2013474. doi:\n                        10.1038\/sj.bjc.6605779","journal-title":"Br J Cancer"},{"issue":"11","key":"3341_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jjco\/hym116","volume":"37","author":"N Yonemoto","year":"2007","unstructured":"Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37(11):843\u2013851. doi:\n                        10.1093\/jjco\/hym116","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"3341_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4143\/crt.2014.308","volume":"47","author":"JO Park","year":"2015","unstructured":"Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY (2015) Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat 47(3):343\u2013361. doi:\n                        10.4143\/crt.2014.308","journal-title":"Cancer Res Treat"},{"issue":"30","key":"3341_CR13","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP (2010) Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28(30):4581\u20134586. doi:\n                        10.1200\/JCO.2010.29.3605","journal-title":"J Clin Oncol"},{"issue":"1","key":"3341_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13193-015-0443-7","volume":"7","author":"SK Singh","year":"2016","unstructured":"Singh SK, Talwar R, Kannan N, Tyagi AK, Jaiswal P, Kumar A (2016) Chemotherapy compared with best supportive care for metastatic\/unresectable gallbladder cancer: a non-randomized prospective cohort study. Indian J Surg Oncol 7(1):25\u201331. doi:\n                        10.1007\/s13193-015-0443-7","journal-title":"Indian J Surg Oncol"},{"issue":"1","key":"3341_CR15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/1097-0142(197807)42:1<330::AID-CNCR2820420150>3.0.CO;2-F","volume":"42","author":"MD Perpetuo","year":"1978","unstructured":"Perpetuo MD, Valdivieso M, Heilbrun LK, Nelson RS, Connor T, Bodey GP (1978) Natural history study of gallbladder cancer: a review of 36\u00a0years experience at M. D. Anderson Hospital and Tumor Institute. Cancer 42(1):330\u2013335","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3341-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:33:59Z","timestamp":1498041239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3341-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3341-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}